The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (GNI) armamentarium. Despite the launch of antibiotics such as Avycaz / Zavicefta, Zerbaxa, Vabomere, Xerava, and Zemdri, unmet needs remain for additional effective treatment options. Commercial opportunities exist for emerging therapies with efficacy in patients with drug-resistant infections, especially those associated with high rates of mortality. However, the market is heavily genericized, and cost containment measures may limit commercial success.

QUESTIONS ANSWERED

  • What are the drivers and constraints in the HT-GNI market, and how will the market evolve over the forecast period? How will rising antibiotic resistance rates and the entry of new generics shape the market?
  • How large are the different GNI indications? What are the resistance rates to different classes of antibiotics across several pathogen species?
  • How will different emerging therapies targeting antibiotic-resistant pathogens address current unmet needs? What emerging therapies do infectious disease (ID) specialists consider as the most promising, and where will these therapies be used?
  • What attributes will emerging therapies need to improve on in order to compete with currently marketed products? What challenges will they face?

Geographies: United States, EU5, Japan

Primary Research: More than 20 country-specific interviews with thought-leading infectious diseases specialists supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed events of GNIs, segmented by key indications (NP, cSSSIs/SSIs, BSIs, cIAIs, UTIs), pathogens (E. coli, Pseudomonas, Acinetobacter, Klebsiella), resistance, and country.

FORECAST: Ten-year, annualized, drug-level sales and patient share of key GNI therapies through 2028, segmented by brands / generics, geography, and five key indications.

Emerging Therapies: Phase III / PR: 11 drugs. Phase II: 4 drugs; coverage of select preclinical and Phase I products

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • HTGNI - Key Findings
    • Key Updates
      • December 2019
      • September 2019
      • June 2019
      • December 2018
      • September 2018
      • August 2018
      • June 2018
      • September 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Hospital-Treated Gram-Negative Infections?
        • What Factors Are Constraining the Market for Hospital-Treated Gram-Negative Infections?
      • Drug-Class-Specific Trends
        • Cephalosporins
        • Beta-Lactam/Beta-Lactamase Inhibitor Combinations
        • Carbapenems
        • Aminoglycosides
        • Tetracyclines
        • Quinolones
        • Phosphomycins
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Key Findings
        • Expert Insight
        • Disease Overview
      • Nosocomial Pneumonia
        • Etiology
        • Pathophysiology
      • Skin and Skin Structure and Surgical-Site Infections
        • Etiology
        • Pathophysiology
      • Urinary Tract Infections
        • Etiology
        • Pathophysiology
      • Intra-Abdominal Infections
        • Etiology
        • Pathophysiology
      • Bloodstream Infections
        • Etiology
        • Pathophysiology
      • Common Gram-Negative Pathogens in Hospital-Treated Infections
        • Enterobacteriaceae
        • Pseudomonads
        • Acinetobacter
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Events of Hospital-Treated UTIs Due to Gram-Negative Pathogens
        • Diagnosed Events of Hospital-Treated BSIs Due to Gram-Negative Pathogens
        • Diagnosed Events of Hospital-Treated NPs Due to Gram-Negative Pathogens
        • Diagnosed Events of Hospital-Treated cIAIs Due to Gram-Negative Pathogens
        • Diagnosed Events of Hospital-Treated SSIs and cSSSIs Due to Gram-Negative Pathogens
        • Diagnosed and Drug-Treated Populations
        • Gram-Negative Pathogens
        • Antimicrobial Resistance to ESCs
        • Antimicrobial Resistance to CPs
        • Antimicrobial Resistance to FQs
    • Current Treatment
      • Key Findings
      • Key Drug-Resistant Pathogens
        • ESKAPE Pathogens
        • Quinolone-Resistant Pseudomonas Aeruginosa
        • Third-Generation Cephalosporin-Resistant Klebsiella Pneumoniae
      • Treatment Goals
        • Key Physician Insights on Clinical Endpoints
      • Key Current Therapies
        • Overview
        • Cephalosporins
        • Beta-Lactam/Beta-Lactamase Inhibitor Combinations
        • Carbapenems
        • Aminoglycosides
        • Tetracyclines
        • Quinolones
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Key Findings
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Hospital-Treated Gram-Negative Infections
        • Future Attainment of Unmet Needs in Hospital-Treated Gram-Negative Infections
        • Unmet Need and Opportunities in Gram-Negative Infections Due to ESBL-Producing Pathogens
        • Unmet Need and Opportunities in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Due to Carbapenem-Resistant Organisms
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Cephalosporins
        • Beta-Lactam/Beta-Lactamase Inhibitor Combinations
        • Carbapenems/Penems
        • Aminoglycosides
        • Tetracyclines
        • Quinolones
        • Phosphomycins
        • Outer Membrane Protein-Targeting Antibiotics
      • Early-Phase Pipeline Analysis
      • Nontraditional Therapies
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • Europe
        • Japan
      • Looking for More?
    • Methodology
      • Market Forecast Assumptions File
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Bibliography

Author(s): Archita Kukreja; Fjoralba Kristo, MD, MPH

Archita is a member of Decision Resources Group’s Infectious, Niche, and Rare Diseases (INRD) team. In this role she works on a range of antibacterial and antiviral indications as well as numerous niche and rare diseases. Archita holds a Masters in Science degree in biotechnology from Jamia Millia Islamia, New Delhi and has completed her MBA from Amity University, Noida.

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods. Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.